Decitabine (NSC 127716)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

102 publications

Decitabine (NSC 127716) Chemical Structure

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Selleck's Decitabine (NSC 127716) has been cited by 102 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MX3GeY5kfGmxbjDBd5NigQ>? MXOwMlXDqM7:TR?= MkW5NlQhcA>? NXqze5k4f2G2ZYK= MknHcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> NY\pcJJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 NXHrZXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH6NE42NzJwNT:1JO69VQ>? Mon3NlQwPDhxN{KgbC=> MVj3ZZRmeg>? NV3IOYl2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MojRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 MXzGeY5kfGmxbjDBd5NigQ>? MmHPNE42yqEQvF2= Ml3FOk8yOi9{NDDo M2GzWJdifGW{ NGTtc4xqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 MknoSpVv[3Srb36gRZN{[Xl? MWGwMlXDqM7:TR?= MVWyOEBp MYT3ZZRmeg>? M4\pRolvcGmkaYTzJINmdGxiaX72ZZNqd25? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO1[osxNjYEoN88US=> M{XwfVI1KGh? MV\3ZZRmeg>? M3jVNIlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> M{ji[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 NUH5XZZwTnWwY4Tpc44hSXO|YYm= MWSwMlUwOSEQvF2= MlvGNlQhcA>? MVf3ZZRmeg>? M1\xZYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116  NVPPZYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nNSVAvPS9zL{KvOUDPxE1? M4DtPFQ5KGh? MlzmSG1UVw>? MYHlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NH\wTHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
LOVO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGzNE42NzFxMj:1JO69VQ>? NIDzTGo1QCCq M{O4PWROW09? MkP1[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116  MVjGeY5kfGmxbjDBd5NigQ>? NV;zcIZoOTBizszN MVi0PEBp NIXaPFNFVVOR M4XqdYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO NGf0fXJHfW6ldHnvckBCe3OjeR?= NXrjbGRlOTBizszN M{XBdVQ5KGh? NUfUNJJlTE2VTx?= M1jYfolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? M1T4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
SW1116  MWXBdI9xfG:|aYOgRZN{[Xl? NVrJR5VyOTBizszN M4HXOVQ5KGh? NYeze3lETE2VTx?= MlW0[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NYryTlhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO MWDBdI9xfG:|aYOgRZN{[Xl? NILi[WcyOCEQvF2= NWrMNIRoPDhiaB?= M1zKTGROW09? NYm0c5pr\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ M1TPR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
RPMI-8226 MofXRZBweHSxc3nzJGF{e2G7 M{\RdVEwOiEQvF2= NEPKcpc1QC95Mj:5OkBp MoTqSG1UVw>? NWGzSoNRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4Pa[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
OPM-2  MU\BdI9xfG:|aYOgRZN{[Xl? NFfhW44yNzJizszN MXG3Nk86Pi9zMkCgbC=> MnqySG1UVw>? MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3u3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
JJN3  MnfCRZBweHSxc3nzJGF{e2G7 MX6wMlUwOSEQvF2= M33xb|I1NzR6IHi= MoTmSG1UVw>? M1rx[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHjTW|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
NCI-H929  M1X0R2Fxd3C2b4Ppd{BCe3OjeR?= NUXQXVFDOS9{IN88US=> NGXZWGM4Oi97Nj:xNlAhcA>? NH;VfWtFVVOR NU\OcFZtcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4fZ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
RPMI-8226 NHXnSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13tTFEwOiEQvF2= M2Lyd|I1NzR6L{eyJIg> NFuxRW5FVVOR M1r2ZYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NIP4Vnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
OPM-2  NYH4V2lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHOWmwyNzJizszN MnPTNlQwPDhxN{KgbC=> M2C2VGROW09? NXT4dopD[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3  NFH0ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXTO5YxNjVxMTFOwG0> M2flTlI1NzR6L{eyJIg> MXHEUXNQ M2DRUoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NVnIbnpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlztNU8zKM7:TR?= MWiyOE81QC95MjDo NFjTRllFVVOR NUnpblNH[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa M2m0d2tqdmG|ZTDBd5NigQ>? MlfKT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> MmnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
HeLa NX;2NmM5U2mwYYPlJGF{e2G7 M33reGtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> NXnYeINxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa MWTLbY5ie2ViQYPzZZk> NWLUTmtvU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
HeLa MWPLbY5ie2ViQYPzZZk> MUnLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NEDlZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
NB4 M1fhd2Z2dmO2aX;uJGF{e2G7 M2X0[lIvPS93L{euOU8yOCEQvF2= MXyyOEBp MXPEUXNQ Mk[zbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NEi3NEc,OjR2OES4O|A9N2F-
CD4+ CD25− T  NUP5PIZQTnWwY4Tpc44hSXO|YYm= M{HaTVEwPSEQvF2= M1TwVJJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? M1P0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe2N|YxLz5{NES3OlM3ODxxYU6=
BV-173 MV3BdI9xfG:|aYOgRZN{[Xl? NXzV[HVsOC5{NT:wMlUwOC55NT:xJO69VQ>? Mn7WOFgwPzJxOU[gbC=> NVvqblRlyqCSQmO= M37tbolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NHLwPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 NULKeoNHSXCxcITvd4l{KEG|c3H5 Mn3rNE4zPS9yLkWvNE44PS9zIN88US=> MoXsOFgwPzJxOU[gbC=> M2SxeeKhWEKV NIDhOoJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 NE\HOYVCeG:ydH;zbZMhSXO|YYm= NVLR[o1VOC5{NT:wMlUwOC55NT:xJO69VQ>? NXLKO|NUPDhxN{KvPVYhcA>? NYfaNVRVyqCSQmO= NE\nWGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MmjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
KG-1a M1TxXmFxd3C2b4Ppd{BCe3OjeR?= Mn7aNE4zPS9yLkWvNE44PS9zIN88US=> MWK0PE84Oi97NjDo MUJCpHBDWw>? MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NH\ueFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
BV-173 NXXCUJJNTnWwY4Tpc44hSXO|YYm= MUWyOVAwPTBybl2= NX;DZXRMPDhiaB?= Ml\lxsBRSlN? NFzLVFJqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NGLyVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
CEM NYLrVGI6TnWwY4Tpc44hSXO|YYm= NYq2T49NOjVyL{WwNI5O M2qzfVQ5KGh? M{jiZuKhWEKV MonybY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 MWLGeY5kfGmxbjDBd5NigQ>? M{HRU|I2OC93MEDuUS=> M4jxU|Q5KGh? Mnm4xsBRSlN? NFv1NmRqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NI\UfZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 Mor3SpVv[3Srb36gRZN{[Xl? Mnq4NlUxNzVyMH7N MWq0PEBp MmrFxsBRSlN? NHrIPZNqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NELqfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
DLD-1 M4LmcWZ2dmO2aX;uJGF{e2G7 M1vvdFI2OC93MEDuUS=> M{e5Z|Q5KGh? MYhCpHBDWw>? NEDIOJBldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NFL5PHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
HCT-116 NX\6dmt6TnWwY4Tpc44hSXO|YYm= NVr6[HhROjVyL{WwNI5O NIP2R2c1QCCq NHXGXlPDqFCEUx?= NFG1WoRldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NIqzepU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
U937-A/E-9/14/18  NHftS3VCeG:ydH;zbZMhSXO|YYm= MYCwMlAyNzBwMT:xM|ExKM7:TR?= NITLVJg1QCCq MnnjbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIXCdXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOwNFQ2Pid-MkSzNFA1PTZ:L3G+
HT29 NF73RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\PfFZHPzJiaB?= NWXZd28{UUN3ME2xOFAxyrFzN{mg{txO M4DEVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUeyNFYyLz5{NEG3NlA3OTxxYU6=
SW48 NH7Me|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Nc5k4OiCq M{\uXGlEPTB;MUWuNuKyPi5{IN88US=> NU\iNmRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|IxPjFpPkK0NVczODZzPD;hQi=>
HCT116 NGfOVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITjZpo4OiCq NIS0dJpKSzVyPUGuO:KyOC52IN88US=> MljQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
HepG2 M2DE[mZ2dmO2aX;uJGF{e2G7 NEX4fVUxNjVxMTFOwG0> NXrjNXJrOjRiaB?= MVTEUXNQ M1WzbpVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M3vyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T NEPEPJpHfW6ldHnvckBCe3OjeR?= NFjPfXoxNjVxMTFOwG0> MkH6NlQhcA>? NXvxO3p7TE2VTx?= MnP2cIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= M2D0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HepG2 NXexUItOSXCxcITvd4l{KEG|c3H5 MY[xM|ExNzFyMDFOwG0> M2G4[Vch\A>? NXzmT4RnTE2VTx?= MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T M4PPR2Fxd3C2b4Ppd{BCe3OjeR?= M2LvTFEwOTBxMUCwJO69VQ>? M1roe|ch\A>? NYD4elgzTE2VTx?= NF:4TXdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2XvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939 NHq5U45CeG:ydH;zbZMhSXO|YYm= MX:xM|ExNzFyMDFOwG0> MWW3JIQ> NEDoU2ZFVVOR MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
U251 NGDLPG5CeG:ydH;zbZMhSXO|YYm= MmjkNU8yOC9zMECg{txO M4Tjb|ch\A>? MV3EUXNQ MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVHMO4pbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
HL-60 M1qzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnGVlRyOSEQvF2= Mk[4OFghcA>? MX\pcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMECzNlQoRjJ2MECwN|I1RC:jPh?=
MDA‑MB‑453 M4HTcGZ2dmO2aX;uJGF{e2G7 M1\6dFAvOi9zIN88US=> MYS3NkBp MX7jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NUjjRnZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQzOjhpPkKzPFQ1OjJ6PD;hQi=>
HCC1569 M3\zTWZ2dmO2aX;uJGF{e2G7 M4XVNVAvOi9zIN88US=> MlPkO|IhcA>? MV\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M4XGflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
BT‑474 NGPRWGRHfW6ldHnvckBCe3OjeR?= NFnaT2YxNjJxMTFOwG0> NGm3XlQ4OiCq MWHjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NI\YR|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
AGS MnrORZBweHSxc3nzJGF{e2G7 M3TOdVUwOTBxMkCvOVAh|ryP MXy0POKhcMLi MmjiSG1UVw>? MWDpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> M13oRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
A549 M{HudGFxd3C2b4Ppd{BCe3OjeR?= NV\JenYxPS9zMD:yNE82OCEQvF2= MV60POKhcMLi NXf5bIpITE2VTx?= MoG1bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> M4XmNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
AGS  M{TEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT0OU8yOC9{MD:1NEDPxE1? NVH6d|NDPDkEoHlCpC=> MojESG1UVw>? NFXPbVlqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> M4L4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
Kasumi-1 NX3NNYlZSXCxcITvd4l{KEG|c3H5 NUDo[IlMOC53IN88US=> Mn\SOFjDqGkEoB?= MWfk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MoDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ|NEmzN|Q5RC:jPh?=
OCI-AML3 MknaRZBweHSxc3nzJGF{e2G7 M1nmdFIvPSEQvF2= MkfiOFjDqGkEoB?= M1HpWoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj M1zTblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
MV4-11 NFW0OlFCeG:ydH;zbZMhSXO|YYm= NHLMNFczNjVizszN NIfob4o1QMLiaNMg MmX4[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M{HkVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
NK  M4[1SWN6fG:2b4jpeJkhSXO|YYm= MlexNE4xOi1{MDFOwG0> NXr5OYkzPSCm MmLV[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NULifYFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgxQDhpPkKzN|I5ODh6PD;hQi=>
NK  NGLrZ5VCeG:ydH;zbZMhSXO|YYm= M2HiNFAvODJvMkCg{txO NFHKdVY2KGR? M4nBToRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? MnS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MkiwPFgoRjJ|M{K4NFg5RC:jPh?=
NK  NHXwRXNHfW6ldHnvckBCe3OjeR?= MnT6NE4xOS1{MDFOwG0> Mm\WOUBl NUe3ZXF3[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? NF7xPFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
MOLT4/DNR NEDwPI1HfW6ldHnvckBCe3OjeR?= NEW0VpE2KM7:TR?= MmTnOEBl MYXy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NW\SWJN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX MmjKSpVv[3Srb36gRZN{[Xl? M4HrblUh|ryP M1\aelQh\A>? MX\y[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NYDvU|E6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
MOLT4/DNR MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe1JO69VQ>? NWfJeGl1PCCm MYTy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O|A9N2F-
Jurkat/DOX MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH4dHE2KM7:TR?= NV\mW2NWPCCm MlPNdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NE\rN4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
ccRCC  MmLHRZBweHSxc3nzJGF{e2G7 MoXpNE4xOS1zMN88US=> NVzPRXBrPzJiaB?= NEDkRo9FVVOR MmP3bIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? M4\H[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
TNBC  NEXTUIRCeG:ydH;zbZMhSXO|YYm= M1S5R|AvODFvMUFOwG0> MUO3NkBp NWXwZmltTE2VTx?= MYLoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498 Mn3kRZBweHSxc3nzJGF{e2G7 MX2wMlAyNTFyzszN NVTI[XQ4PzJiaB?= NE\ibY5FVVOR NE\Gc2RqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M{LURVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
KIJ265T MlmzRZBweHSxc3nzJGF{e2G7 MoTWNE4xOS1zMN88US=> MYS3NkBp NVr5T2xOTE2VTx?= MkOybY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M4LNdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
MDA-231 MWTBdI9xfG:|aYOgRZN{[Xl? Mk\HNE4xOS1zMN88US=> NFLETVM4OiCq MmTmSG1UVw>? M4LlN4lv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
BT-20 MnfnRZBweHSxc3nzJGF{e2G7 NFv0R5MxNjBzLUGw{txO MmnBO|IhcA>? NEfHfFdFVVOR NEHtbINqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
U937 NIjwdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK1MVIxKM7:TR?= NUTGWnpCOjRxNEivO|IhcA>? NFTDTHpqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 M1;EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T3PFUuOjBizszN M13rTVI1NzR6L{eyJIg> M{jpZYlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
U937 NXnvNmI4SXCxcITvd4l{KEG|c3H5 NHHXd3gyPSEQvF2= NUezd3BYOjRxNEivO|IhcA>? MnvQbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 MkjPRZBweHSxc3nzJGF{e2G7 MUexOUDPxE1? NVzqS5N4OjRxNEivO|IhcA>? NXTOVZpGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
LS411N  Mk\ERZBweHSxc3nzJGF{e2G7 MWewMlUh|ryP MkfOO|IhcA>? NYToNFg6cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs M3nUOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NE[xOlk2Lz5{MkS2NVY6PTxxYU6=
MDA-MB-231 MlrIRZBweHSxc3nzJGF{e2G7 NIHu[mcyOCEQvF2= Moi3OFghcA>? M1zRepJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M33POFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi3Olk4Lz5{MUi4O|Y6PzxxYU6=
MCF-7  NHLNcpdCeG:ydH;zbZMhSXO|YYm= MX:xNEDPxE1? NH\VR3o1QCCq MXLy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVuw[5JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
A375 NEKzWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmc4ExNjVizszN NXzFS2N3OS93L{ig[C=> MkjjbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NFrVfY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nZXlAvPSEQvF2= MWqxM|UwQCCm MUXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M33MZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL3 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jlXlAvPSEQvF2= NFP3[JoyNzVxODDk NYj0NppEcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28 M33iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPkNE42KM7:TR?= M2DtVVEwPS96IHS= MUXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? Mmn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
MeWo NVL2OFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LaZ|AvPSEQvF2= M{S4V|EwPS96IHS= NUXKTXNrcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M33FPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
B16 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfMflgxNjVizszN NGLGUXIyNzVxODDk NWXnXFNDcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NI[wPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
Ly 1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LlRVI1KGh? MXTJR|UxRTdwMzFOwG0> M3nBO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[5bFI1KGh? NIrOUYZKSzVyPUGwMlch|ryP MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 NV7UTJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGyOEBp NVSyUHpTUUN3MP-8olIxKM7:TR?= M4XvN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 NEm5VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LJbFI1KGh? MoPZTWM2OO,:nkKwJO69VQ>? NEGyXmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
RIVA NWjzdmVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqyOEBp NXjNOI9NUUN3MP-8olIxKM7:TR?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 NVTKfFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH6bFh5OjRiaB?= MX\JR|Ux97zgMkCg{txO MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1 M4TE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TPeFQ5KGh? MYrJR|UxRTBwM{Sg{txO MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDNZVY1QCCq Ml3JTWM2OD1yLkCyOUDPxE1? Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL6 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrLOFghcA>? NYXXb2ZCUUN3MP-8olIxKM7:TR?= MlS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 NVPBdmNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zSUFQ5KGh? NW\ydmo4UUN3ME2xMlgh|ryP NUWxW3dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA M3HGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Pyc|Q5KGh? M4LZPGlEPTExvK6yNEDPxE1? M2DnfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 NEnQTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvZbHlxPDhiaB?= MYPJR|UxRTF5LkSg{txO Ml[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrv[VNwPzJiaB?= MVXJR|UxRTBwMEGg{txO NUPGdoE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 NWrodI86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\EUVczKGh? MU\JR|UxRTBwMEG4JO69VQ>? NVW5S|I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL6 NXroW4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DF[|czKGh? M3PPdmlEPTB;MT62JO69VQ>? NYTVdYZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj3W4s4OiCq Mo\TTWM2OD1zLkKg{txO M{ni[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA NVLQPWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u5cFczKGh? NFLMPIpKSzVy78{eNlAh|ryP MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 NYHM[m16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zO|IhcA>? MYTJR|UxRTFzLkKg{txO M2rPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI M{\kWWFvfGm4aYLhcEBie3OjeR?= NFyy[noxNjJ3IITvJFghfU1? NFf0d4ozKHSxIEeyJIhzew>? MkG1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDVOU1o[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI M4nZUGFvfGm4aYLhcEBie3OjeR?= NFTMSZcxNjJ3IITvJFghfU1? NHzId2QzKHSxIEeyJIhzew>? MlviRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhOC5{NTD0c{A5KHWPIHHmeIVzKDJidH:gO|IhcHK|IHL5JJFRS1JibXX0bI9l MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04985656 Not yet recruiting Drug: Pevonedistat|Drug: Decitabine|Drug: Cedazuridine Myelodysplastic Syndromes (MDS) Takeda October 1 2021 Phase 2
NCT04854889 Recruiting Drug: Decitabine Refractory Aplastic Anemia Institute of Hematology & Blood Diseases Hospital April 22 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine (NSC 127716) | Decitabine (NSC 127716) supplier | purchase Decitabine (NSC 127716) | Decitabine (NSC 127716) cost | Decitabine (NSC 127716) manufacturer | order Decitabine (NSC 127716) | Decitabine (NSC 127716) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID